---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035948"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T02:14:21.739459+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs to acquire Stella Diagnostics' BE-Smart esophageal cancer test for approx $4.5M

## Summary
- Total consideration ~$4.5M ($3.5M cash + 100k shares of PRPH common stock); up to $2M additional PRPH shares upon commercial milestone.
- BE-Smart test showed >99% sensitivity/specificity on >200 human samples; aims for commercialization within 18 months.
- Target market: Barrett's esophagus affects 3-6M US patients; potential reimbursement $1,000–$3,000 per test.
- Transaction expected to close early January 2023, subject to Stella shareholder approval.
- Stella to receive 5% royalty on adjusted gross margin from commercialized IP.

## SEC filing metadata
- accession: 0001493152-22-035948
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/0001493152-22-035948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035948
- JSON: https://secwatch.observer/filing/0001493152-22-035948.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035948.txt

## Key facts
- Material Agreements
  ProPhase Labs, Inc. entered into Asset Purchase Agreement with Stella Diagnostics Inc. and Stella DX, LLC valued at $3,486,000 in cash (effective 2022-12-15).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Stella Diagnostics Inc. and Stella DX, LLC
  - Value: $3,486,000 in cash
  - Effective: 2022-12-15
  source text: On December 15, 2022, ProPhase Labs, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), by and among the Company and Stella Diagnostics Inc. (“Stella”) and Stella DX, LLC (“Stella DX” and, together with Stella, the “Sellers”), pursuant to which the Company will purchase all of the assets, rights and interests of the Sellers and their affiliates pertaining to the Sellers’ BE-Smart Esophageal Pre-Cancer diagnostic screening test and certain clinical assets, including all intellectual property rights (the “Purchased Assets”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/0001493152-22-035948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.